A subset of TIL-derived samples, mostly from luminal (ER/PR-positive) breast cancers, had a pathway activity profile resembling the immune-tolerant pathway profile found in the tumor SN-treated cells with respect to the PI3K, JAK-STAT3, and TGFβ pathway activities, complemented by higher Notch and NFκB pathway activities. This evidence concerns the gene STAT3 and breast carcinoma.